nach oben

Journal of Neural Transmission

Erschienen in:

04.05.2016 | Neurology and Preclinical Neurological Studies - Review Article

Nrf2: a modulator of Parkinson’s disease?

verfasst von: Michael Todorovic, Stephen A. Wood, George D. Mellick

Erschienen in: Journal of Neural Transmission | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is a complex multifactorial disorder that has been associated with the processes of oxidative stress. In the absence of curative therapies, modification of the neurodegenerative process—including the manipulation of endogenous antioxidant pathways—is the focus of intensive research. Recently, genetic and pharmacological accretion of the transcription factor, and phase II antioxidant ‘master regulator’ Nrf2, has shown to demonstrably mitigate the toxic neuronal effects of parkinsonian agents such as MPP⁺, rotenone, and hydrogen peroxide in vitro and in vivo. Furthermore, baseline genetic variability in Nrf2-dependant pathways may promote neuronal susceptibility to exogenous agents and correlate with PD onset within certain populations. While contemporary evidence directly implicating Nrf2 in the pathogenesis of PD is not conclusive and likely contingent upon the evaluation of complex interacting factors—including genetic variation and a history of environmental exposures—it remains a promising target for therapeutic benefit in the modulation of oxidative stress.

Alfieri A, Srivastava S, Siow RC, Modo M, Fraser PA, Mann GE (2011) Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 589(Pt 17):4125–4136CrossRefPubMedPubMedCentral

Barone MC, Sykiotis GP, Bohmann D (2011) Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson’s disease. Dis Model Mech 4(5):701–707CrossRefPubMedPubMedCentral

Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Markus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, Ashford ML, Wyllie DJ, Scannevin RH, Chandran S, Hayes JD, Hardingham GE (2015) Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. Nat Commun 6:7066CrossRefPubMedPubMedCentral

Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE (1997) A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey. Brain Res 766(1–2):107–112CrossRefPubMed

Birkmayer W, Riederer P, Ambrozi L, Youdim MB (1977) Implications of combined treatment with ‘Madopar’ and l-deprenil in Parkinson’s disease. A long-term study. Lancet 1(8009):439–443CrossRefPubMed

Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2(5):249–253CrossRefPubMed

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed

Carrillo MC, Kanai S, Sato Y, Nokubo M, Ivy GO, Kitani K (1993) The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci 52(24):1925–1934CrossRefPubMed

Castellani R, Smith MA, Richey PL, Perry G (1996) Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737(1–2):195–200CrossRefPubMed

Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, Sudhof TC (2004) Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci USA 101(41):14966–14971CrossRefPubMedPubMedCentral

Chen YC, Wu YR, Wu YC, Lee-Chen GJ, Chen CM (2013) Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson’s disease. Parkinsonism Relat Disord 19(2):247–250CrossRefPubMed

Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP (2006) DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103(41):15091–15096CrossRefPubMedPubMedCentral

Cook AL, Vitale AM, Ravishankar S, Matigian N, Sutherland GT, Shan J, Sutharsan R, Perry C, Silburn PA, Mellick GD, Whitelaw ML, Wells CA, Mackay-Sim A, Wood SA (2011) NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson’s disease. PLoS One 6(7):e21907CrossRefPubMedPubMedCentral

Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909CrossRefPubMed

Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD (2004) Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson’s disease. Ann Neurol 55(6):897CrossRefPubMed

Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A, G. Geoparkinson Study (2007) Gene-environment interactions in parkinsonism and Parkinson’s disease: the Geoparkinson study. Occup Environ Med 64(10):673–680CrossRefPubMedPubMedCentral

Dinkova-Kostova AT, Baird L, Holmstrom KM, Meyer CJ, Abramov AY (2015) The spatiotemporal regulation of the Keap1-Nrf2 pathway and its importance in cellular bioenergetics. Biochem Soc Trans 43(4):602–610CrossRefPubMedPubMedCentral

Dringen R, Kussmaul L, Gutterer JM, Hirrlinger J, Hamprecht B (1999a) The glutathione system of peroxide detoxification is less efficient in neurons than in astroglial cells. J Neurochem 72(6):2523–2530CrossRefPubMed

Dringen R, Pfeiffer B, Hamprecht B (1999b) Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19(2):562–569PubMed

Duffy S, So A, Murphy TH (1998) Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage. J Neurochem 71(1):69–77CrossRefPubMed

Etminan M, Gill SS, Samii A (2005) Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 4(6):362–365CrossRefPubMed

Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301CrossRefPubMed

Fong CS, Wu RM, Shieh JC, Chao YT, Fu YP, Kuao CL, Cheng CW (2007) Pesticide exposure on southwestern Taiwanese with MnSOD and NQO1 polymorphisms is associated with increased risk of Parkinson’s disease. Clin Chim Acta 378(1–2):136–141CrossRefPubMed

Fournier M, Vitte J, Garrigue J, Langui D, Dullin JP, Saurini F, Hanoun N, Perez-Diaz F, Cornilleau F, Joubert C, Ardila-Osorio H, Traver S, Duchateau R, Goujet-Zalc C, Paleologou K, Lashuel HA, Haass C, Duyckaerts C, Cohen-Salmon C, Kahle PJ, Hamon M, Brice A, Corti O (2009) Parkin deficiency delays motor decline and disease manifestation in a mouse model of synucleinopathy. PLoS One 4(8):e6629CrossRefPubMedPubMedCentral

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, Investigators DS (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107CrossRefPubMed

Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM (2012) Genetic modification of the association of paraquat and Parkinson’s disease. Mov Disord 27(13):1652–1658CrossRefPubMedPubMedCentral

Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51–88CrossRefPubMed

Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106(23):9362–9367CrossRefPubMedPubMedCentral

Hong Y, Yan W, Chen S, Sun CR, Zhang JM (2010) The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice. Acta Pharmacol Sinica 31(11):1421–1430CrossRef

Im JY, Lee KW, Woo JM, Junn E, Mouradian MM (2012) DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet 21(13):3013–3024CrossRefPubMedPubMedCentral

Jakel RJ, Townsend JA, Kraft AD, Johnson JA (2007) Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 1144:192–201CrossRefPubMedPubMedCentral

Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, Cuadrado A (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal 14(12):2347–2360CrossRefPubMed

Jennings P, Limonciel A, Felice L, Leonard MO (2013) An overview of transcriptional regulation in response to toxicological insult. Arch Toxicol 87(1):49–72CrossRefPubMed

Jia Z, Zhu H, Misra BR, Li Y, Misra HP (2008) Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinone oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. Neurochem Res 33(11):2197–2205CrossRefPubMed

Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47:89–116CrossRefPubMed

Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Saaksjarvi K, Heliovaara M (2010) Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67(7):808–811CrossRefPubMedPubMedCentral

Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24(5):1101–1112CrossRefPubMed

Lev N, Barhum Y, Ben-Zur T, Aharony I, Trifonov L, Regev N, Melamed E, Gruzman A, Offen D (2015) A DJ-1 based peptide attenuates dopaminergic degeneration in mice models of Parkinson’s disease via enhancing Nrf2. PLoS One 10(5):e0127549CrossRefPubMedPubMedCentral

Li J, Lee JM, Johnson JA (2002) Microarray analysis reveals an antioxidant responsive element-driven gene set involved in conferring protection from an oxidative stress-induced apoptosis in IMR-32 cells. J Biol Chem 277(1):388–394CrossRefPubMed

Li J, Johnson D, Calkins M, Wright L, Svendsen C, Johnson J (2005) Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 83(2):313–328CrossRefPubMed

Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, Chen L, Zhuang X, Hogg J, Pare P, Tuder RM, Biswal S (2008) Expression of concern: decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 178(6):592–604CrossRefPubMedPubMedCentral

Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747–753CrossRefPubMedPubMedCentral

Markesbery WR, Jicha GA, Liu H, Schmitt FA (2009) Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68(7):816–822CrossRefPubMedPubMedCentral

Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR (2007) Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 21(9):2237–2246CrossRefPubMed

Mas S, Gasso P, Trias G, Bernardo M, Lafuente A (2012) Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. Fundam Clin Pharmacol 26(6):712–721CrossRefPubMed

Mateo I, Infante J, Sanchez-Juan P, Garcia-Gorostiaga I, Rodriguez-Rodriguez E, Vazquez-Higuera JL, Berciano J, Combarros O (2010) Serum heme oxygenase-1 levels are increased in Parkinson’s disease but not in Alzheimer’s disease. Acta Neurol Scand 121(2):136–138CrossRefPubMed

Matigian N, Abrahamsen G, Sutharsan R, Cook AL, Vitale AM, Nouwens A, Bellette B, An J, Anderson M, Beckhouse AG, Bennebroek M, Cecil R, Chalk AM, Cochrane J, Fan Y, Feron F, McCurdy R, McGrath JJ, Murrell W, Perry C, Raju J, Ravishankar S, Silburn PA, Sutherland GT, Mahler S, Mellick GD, Wood SA, Sue CM, Wells CA, Mackay-Sim A (2010) Disease-specific, neurosphere-derived cells as models for brain disorders. Dis Model Mech 3(11–12):785–798CrossRefPubMed

Mellick GD (2013) Why we need better nationwide measures of Parkinson’s disease incidence and prevalence in Australia. Australasian Epidemiol 20(1):20–22

Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352(9137):1344–1346CrossRefPubMed

Miyakawa S, Ogino M, Funabe S, Uchino A, Shimo Y, Hattori N, Ichinoe M, Mikami T, Saegusa M, Nishiyama K, Mori H, Mizuno Y, Murayama S, Mochizuki H (2013) Lewy body pathology in a patient with a homozygous parkin deletion. Mov Disord 28(3):388–391CrossRefPubMed

Montgomery EB Jr (1995) Heavy metals and the etiology of Parkinson’s disease and other movement disorders. Toxicology 97(1–3):3–9CrossRefPubMed

Murata H, Takamatsu H, Liu S, Kataoka K, Huh NH, Sakaguchi M (2015) NRF2 REGULATES PINK1 expression under oxidative stress conditions. PLoS One 10(11):e0142438CrossRefPubMedPubMedCentral

Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson”s disease. J Neurosci Res 85(5):919–934CrossRefPubMed

Nakamura K, Wang W, Kang UJ (1997) The role of glutathione in dopaminergic neuronal survival. J Neurochem 69(5):1850–1858CrossRefPubMed

Parkinson Study Group QEI, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K (2014) A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 71(5):543–552

Pickrell AM, Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron 85(2):257–273CrossRefPubMedPubMedCentral

Poewe W (2010) Parkinson disease: treatment of the nonmotor symptoms of Parkinson disease. Nat Rev Neurol 6(8):417–418CrossRefPubMed

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047CrossRefPubMed

Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S (2000) A meta-analysis of Parkinson’s disease and exposure to pesticides. Neurotoxicology 21(4):435–440PubMed

Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66(1):75–85CrossRefPubMedPubMedCentral

Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, Biswal S (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114(9):1248–1259CrossRefPubMedPubMedCentral

Schipper HM, Liberman A, Stopa EG (1998) Neural heme oxygenase-1 expression in idiopathic Parkinson’s disease. Exp Neurol 150(1):60–68CrossRefPubMed

Shih PH, Yen GC (2007) Differential expressions of antioxidant status in aging rats: the role of transcriptional factor Nrf2 and MAPK signaling pathway. Biogerontology 8(2):71–80CrossRefPubMed

Shih HC, Shiozawa T, Miyamoto T, Uchikawa J, Feng Y, Kashima H, Nikaido T, Konishi I (2003) Nuclear localization of beta-catenin is correlated with the expression of cyclin D1 in endometrial carcinomas. Anticancer Res 23(5A):3749–3754PubMed

Shoulson I (1998) DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 44(3 Suppl 1):S160–S166CrossRefPubMed

Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain 132(Pt 7):1795–1809CrossRefPubMedPubMedCentral

Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D (2008) Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 312(1–2):131–138CrossRefPubMed

Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 5:597–610PubMedPubMedCentral

Suh JH, Shenvi SV, Dixon BM, Liu H, Jaiswal AK, Liu RM, Hagen TM (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 101(10):3381–3386CrossRefPubMedPubMedCentral

Sykiotis GP, Habeos IG, Samuelson AV, Bohmann D (2011) The role of the antioxidant and longevity-promoting Nrf2 pathway in metabolic regulation. Curr Opin Clin Nutr Metab Care 14(1):41–48CrossRefPubMedPubMedCentral

Tanner CM, Langston JW (1990) Do environmental toxins cause Parkinson’s disease? A critical review. Neurology 40(10 Suppl 3):Suppl 17–Suppl 30 (discussion 30-11)

Todorovic M, Newman JR, Shan J, Bentley S, Wood SA, Silburn PA, Mellick GD (2015) Comprehensive assessment of genetic sequence variants in the antioxidant ‘master regulator’ nrf2 in idiopathic Parkinson’s disease. PLoS One 10(5):e0128030CrossRefPubMedPubMedCentral

van der Mark M, Brouwer M, Kromhout H, Nijssen P, Huss A, Vermeulen R (2012) Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect 120(3):340–347CrossRefPubMedPubMedCentral

van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, Siegel D, Drukarch B (2004) Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25(9):1253–1262CrossRefPubMed

von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, Hakansson A, Nissbrandt H, Drozdzik M, Bialecka M, Kurzawski M, Blennow K, Nilsson M, Hammarsten O, Zetterberg H (2010) Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson’s disease. BMC Med Genet 11:36CrossRef

von Otter M, Bergstrom P, Quattrone A, De Marco EV, Annesi G, Soderkvist P, Wettinger SB, Drozdzik M, Bialecka M, Nissbrandt H, Klein C, Nilsson M, Hammarsten O, Nilsson S, Zetterberg H (2014) Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson’s disease—a multicenter study. BMC Med Genet 15:131CrossRef

Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AS, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SJ, Wood NW (2008) PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 3(6):e2455CrossRefPubMedPubMedCentral

Xiao H, Lv F, Xu W, Zhang L, Jing P, Cao X (2011) Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology 290(2–3):286–294CrossRefPubMed

Zafar KS, Inayat-Hussain SH, Siegel D, Bao A, Shieh B, Ross D (2006a) Overexpression of NQO1 protects human SK-N-MC neuroblastoma cells against dopamine-induced cell death. Toxicol Lett 166(3):261–267CrossRefPubMed

Zafar KS, Siegel D, Ross D (2006b) A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 70(3):1079–1086CrossRefPubMed

Zhou W, Freed CR (2005) DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280(52):43150–43158CrossRefPubMed

Titel: Nrf2: a modulator of Parkinson’s disease?
verfasst von: Michael Todorovic
Stephen A. Wood
George D. Mellick
Publikationsdatum: 04.05.2016
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 6/2016
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-016-1563-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Nrf2: a modulator of Parkinson’s disease?

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease

Olfactory dysfunction is related to postoperative delirium in Parkinson’s disease

Multiple system atrophy: pathogenic mechanisms and biomarkers

Arachnophobia alleviated by subthalamic nucleus stimulation for Parkinson’s disease

Executive functioning and risk-taking behavior in Parkinson’s disease patients with impulse control disorders

Stride time variability as a marker for higher level of gait control in multiple sclerosis: its association with fear of falling

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Update Neurologie